Both suppression of NF-κB (an important transcription factor regulating inflammatory response) and increased NO production have been suggested as an anti-inflammatory strategy in inflammatory bowel disease (IBD) and in rheumatoid arthritis (AR). The gene discussed is NFKB1; the disease is inflammatory bowel disease.